BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32522824)

  • 1. p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer.
    Xu S; Fan L; Jeon HY; Zhang F; Cui X; Mickle MB; Peng G; Hussain A; Fazli L; Gleave ME; Dong X; Qi J
    Cancer Res; 2020 Aug; 80(15):3074-3087. PubMed ID: 32522824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.
    Fan L; Peng G; Sahgal N; Fazli L; Gleave M; Zhang Y; Hussain A; Qi J
    Oncogene; 2016 May; 35(19):2441-52. PubMed ID: 26279298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.
    Fan L; Zhang F; Xu S; Cui X; Hussain A; Fazli L; Gleave M; Dong X; Qi J
    Proc Natl Acad Sci U S A; 2018 May; 115(20):E4584-E4593. PubMed ID: 29712835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells.
    Fan L; Xu S; Zhang F; Cui X; Fazli L; Gleave M; Clark DJ; Yang A; Hussain A; Rassool F; Qi J
    Cell Death Dis; 2020 Apr; 11(4):214. PubMed ID: 32238799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
    Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
    Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 7. Histone demethylase JMJD1A in cancer progression and therapeutic resistance.
    Jeon HY; Ryu H; Pornour M; Qi J
    Mol Carcinog; 2022 Apr; 61(4):392-396. PubMed ID: 35020958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
    Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
    Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
    [No Abstract]   [Full Text] [Related]  

  • 10. Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.
    Xu P; Yang JC; Ning S; Chen B; Nip C; Wei Q; Liu L; Johnson OT; Gao AC; Gestwicki JE; Evans CP; Liu C
    Pharmacol Res; 2023 Mar; 189():106692. PubMed ID: 36773708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
    Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
    J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.
    Liu C; Lou W; Yang JC; Liu L; Armstrong CM; Lombard AP; Zhao R; Noel ODV; Tepper CG; Chen HW; Dall'Era M; Evans CP; Gao AC
    Nat Commun; 2018 Nov; 9(1):4700. PubMed ID: 30446660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kwon GY; Kim JH
    Oncogene; 2018 Mar; 37(10):1326-1339. PubMed ID: 29249800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
    Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
    J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases.
    Lee HY; Yang EG; Park H
    Carcinogenesis; 2013 Dec; 34(12):2706-15. PubMed ID: 23884959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.
    Wang J; Zhang H; Zhang X; Wang P; Wang H; Huang F; Zhou C; Zhou J; Li S
    Oncotarget; 2016 Dec; 7(49):81377-81388. PubMed ID: 27835608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
    Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
    Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective degradation of AR-V7 to overcome castration resistance of prostate cancer.
    Liu Y; Yu C; Shao Z; Xia X; Hu T; Kong W; He X; Sun W; Deng Y; Liao Y; Huang H
    Cell Death Dis; 2021 Sep; 12(10):857. PubMed ID: 34548474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells.
    Liu W; Wang C; Wang S; Zeng K; Wei S; Sun N; Sun G; Wang M; Zou R; Liu W; Lin L; Song H; Jin Z; Zhao Y
    Int J Biol Sci; 2021; 17(1):188-203. PubMed ID: 33390843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.